Prelude Therapeutics (PRLD) director receives 38,000 stock option grant

Rhea-AI Filing Summary

Prelude Therapeutics Inc director Martin Babler received a grant of options to buy 38,000 shares of common stock as compensation. The options have an exercise price of $3.94 per share and expire on June 8, 2036.

The award will fully vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, subject to his continued service. Following this grant, Babler directly holds options for 38,000 underlying common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Babler Martin

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	38,000	$0.00	--

Holdings After Transaction: Director Stock Option (Right to Buy) — 38,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 38,000 options Underlying shares: 38,000 shares Exercise price: $3.94 per share +2 more

5 metrics

Options granted 38,000 options Director stock option grant for common stock

Underlying shares 38,000 shares Common stock underlying the director stock option

Exercise price $3.94 per share Strike price of the granted options

Expiration date June 8, 2036 Option award expiration

Holdings after grant 38,000 options Total derivative securities held following transaction

Key Terms

Director Stock Option (Right to Buy), exercise price, expiration date, grant, award, or other acquisition, +1 more

5 terms

Director Stock Option (Right to Buy) financial

"security_title: Director Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 3.9400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-08T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

annual stockholder meeting financial

"The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting"

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Babler Martin

(Last) (First) (Middle)

C/O PRELUDE THERAPEUTICS INCORPORATED

175 INNOVATION BOULEVARD

(Street)

WILMINGTON DELAWARE 19805

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Prelude Therapeutics Inc [ PRLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$3.94	06/09/2026		A		38,000		(1)	06/08/2036	Common Stock	38,000	$0.00	38,000	D

Explanation of Responses:

1. The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

	/s/ Bryant D. Lim, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Prelude Therapeutics (PRLD) report for Martin Babler?

Prelude Therapeutics reported that director Martin Babler received a grant of options for 38,000 shares of common stock. The options are compensation-related, carry a $3.94 exercise price, and give him the right to buy shares at that price before expiration.

How many Prelude Therapeutics (PRLD) shares are covered by Martin Babler’s new options?

The option award covers 38,000 underlying shares of Prelude Therapeutics common stock. These are derivative securities that, once vested and exercised at the $3.94 strike price, would convert into an equal number of common shares, subject to the stated expiration date.

What is the exercise price of Martin Babler’s Prelude Therapeutics (PRLD) stock options?

The options granted to director Martin Babler have an exercise price of $3.94 per share. This means he can purchase Prelude Therapeutics common stock at $3.94 per share upon vesting and exercise, regardless of the market price at that time, until the options expire.

When do Martin Babler’s Prelude Therapeutics (PRLD) options vest?

The options will fully vest on the earlier of Prelude Therapeutics’ next annual stockholder meeting or the one-year anniversary of the grant date. Vesting is conditional on Babler continuing to provide service to the company on each applicable vesting date, according to the footnote.

When do the newly granted Prelude Therapeutics (PRLD) options expire?

The granted director stock options expire on June 8, 2036. After this expiration date, any unexercised portion of the 38,000-share option award will lapse, and the right to purchase Prelude Therapeutics common stock at the $3.94 strike price will no longer be available.

How many Prelude Therapeutics (PRLD) options does Martin Babler hold after this grant?

After the grant, Martin Babler holds options for 38,000 underlying shares of Prelude Therapeutics common stock. The Form 4 shows this as his total derivative holdings following the transaction, reflecting the full amount of the newly awarded director stock option grant.